Literature DB >> 27389727

Pericardial effusion with Mycobacterium avium complex in HIV-infected patients.

Thajunnisha Mohamed Buhary1, Sedki Latif Gayed1, Irfan Hafeez2.   

Abstract

Disseminated atypical Mycobacterium infection is a well-known opportunistic infection in HIV-infected patients with advanced immune deficiency before the introduction of combination antiretroviral therapy. Although the disseminated infection is now rare, few cases of localised infections are reported. A 38-year-old man was diagnosed with HIV infection during asymptomatic sexual health screening. Although he was asymptomatic on diagnosis, he had advanced immunodeficiency; therefore, combination antiretroviral therapy was started immediately. After 5 months of treatment, he developed pericardial effusion. Mycobacterium was detected from a culture of the pericardial fluid and Mycobacterium avium complex was identified using a gene probe test. He was treated with combination therapy for Mycobacterium infection and he fully recovered. Treatment continued for 4 years until he achieved adequate immune recovery. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27389727      PMCID: PMC4956986          DOI: 10.1136/bcr-2016-215686

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Multiplex PCR provides a low-cost alternative to DNA probe methods for rapid identification of Mycobacterium avium and Mycobacterium intracellulare.

Authors:  D Cousins; B Francis; D Dawson
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

2.  AIDS across Europe, 1994-98: the EuroSIDA study.

Authors:  A Mocroft; C Katlama; A M Johnson; C Pradier; F Antunes; F Mulcahy; A Chiesi; A N Phillips; O Kirk; J D Lundgren
Journal:  Lancet       Date:  2000-07-22       Impact factor: 79.321

3.  Mediastinitis and pericardial effusion in a patient with AIDS and disseminated Mycobacterium avium infection: a case report.

Authors:  Juan José Cortez-Escalante; Aline Marques Dos Santos; Giovanna de Curcio Garnica; Ana Lucia Sarmento; Cleudson Nery de Castro; Gustavo Adolfo Sierra Romero
Journal:  Rev Soc Bras Med Trop       Date:  2012-06       Impact factor: 1.581

4.  Cerebral mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated mycobacterium avium complex infection.

Authors:  R Murray; S Mallal; C Heath; M French
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-03       Impact factor: 3.267

5.  Rapid identification using a specific DNA probe of Mycobacterium avium complex from patients with acquired immunodeficiency syndrome.

Authors:  T E Kiehn; F F Edwards
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

Review 6.  Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.

Authors:  Petros C Karakousis; Richard D Moore; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2004-09       Impact factor: 25.071

7.  Fatal pericarditis due to Mycobacterium avium-intracellulare in acquired immunodeficiency syndrome.

Authors:  G L Woods; J C Goldsmith
Journal:  Chest       Date:  1989-06       Impact factor: 9.410

Review 8.  Cardiac tamponade in patients with human immunodeficiency virus disease.

Authors:  Ramesh M Gowda; Ijaz A Khan; Nirav J Mehta; Mamatha R Gowda; Terrence J Sacchi; Balendu C Vasavada
Journal:  Angiology       Date:  2003 Jul-Aug       Impact factor: 3.619

9.  Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients.

Authors:  S D Nightingale; L T Byrd; P M Southern; J D Jockusch; S X Cal; B A Wynne
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

10.  Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy.

Authors:  Judith A Aberg; Peter V Chin-Hong; Allen McCutchan; Susan L Koletar; Judith S Currier
Journal:  Clin Infect Dis       Date:  2002-06-04       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.